FDC Limited share price
NSE: FDC · ISIN INE258B01022
Key numbers
- Market cap
- ₹ 5,552 Cr
- Current price
- ₹ 341.00
- 52-week high / low
- ₹ 476 / 313
- Stock P/E
- 19.0
- Book value
- ₹ 152.6
- Dividend yield
- 2.93%
- ROCE
- 15.8%
- ROE
- 11.8%
- Debt to equity
- 0.01
- Sales growth (3 yrs)
- 6.8%
- Profit growth (3 yrs)
- 13.2%
- 1-year return
- -28.7%
About FDC Limited
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastroenterology, ophthalmology, anti-diabetics, cardiovascular care, respiratory care, gynaecology, dermatology, paediatrics, analgesics, vitamins, and nutritional health in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured oral rehydration solution powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zifi-0, Zocon, Mycoderm, Zathrin, Victofol, Cotaryl, Ziglim-M, Amodep-AT, MumMum 1, Victofol Injection, Simyl MCT, Victofol C, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 648 | 473 | 465 | 585 | 668 |
| Operating profit | 140 | 34 | 52 | 106 | 143 |
| Net profit | 121 | 28 | 28 | 103 | 132 |
| EPS (₹) | 7.45 | 1.75 | 1.74 | 6.35 | 8.14 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.